theMednetRegister

Journal Club ft. NEJM publications   

Questions discussed in this category

For neoadjuvant treatment of muscle invasive bladder cancer, are you utilizing durvalumab plus gemcitabine cisplatin over dose dense or accelerated MVAC?
Were you using gem/cis or ddMVAC more routinely prior to NIAGRA?
1 Answer available
Would you consider omitting adjuvant durvalumab in MIBC to limit overtreatment in patients who may not benefit or those who have achieved maximal benefit after neoadjuvant gem/cis/durva?
3 Answers available
Do you plan to extrapolate from the NIAGARA trial regarding peri-operative durvalumab/cis/gem to treat upper tract urothelial carcinoma?
5 Answers available
Will you offer adjuvant nivolumab for high-risk muscle invasive bladder cancer based on results of CheckMate 274?
5 Answers available
Would you recommend adjuvant cisplatin/gemcitabine or nivolumab in a patient with muscle invasive bladder CA who proceeded to radical cystectomy first?
6 Answers available
Which patients with muscle invasive bladder cancer will you treat with adjuvant nivolumab?
How do prior chemotherapy, site of disease, and pathological staging inform your decision? How about molecular markers (PD-L1, ctDNA)?
5 Answers available
What are the main practical factors to consider when using bispecific antibody therapy (Tarlatamab) for extensive-stage small cell lung cancer?
4 Answers available
Would you use T-DXd or capecitabine/trastuzumab/tucatinib for HER2+ metastatic breast cancer with predominantly CNS progression after THP?
Which regimen is preferred in second line for these patients? What is the efficacy of TDXd vs tucatinib in CNS metastases?    
6 Answers available
Is the phase 2 data regarding neoadjuvant cemiplimab in cutaneous squamous cell carcinoma sufficient to adopt for all patients or will you await phase 3 data?
6 Answers available
In which breast cancer presentation would you consider earlier treatment with T-DXd, given the similar absolute PFS benefits seen with T-DXd in the DESTINY-Breast06 trial and DESTINY-Breast04 trials?
3 Answers available
How are you requesting testing for HER2-ultralow status, in light of DB-06 trial demonstrating benefit of T-DXd for these patients?
3 Answers available
When, if ever, would you select a three-drug regimen instead of four-drug regimen in patients with newly diagnosed Multiple Myeloma?
3 Answers available
What is your preferred first line treatment regimen for patients with untreated transplant-ineligible MM?
Triplet v. Quadruplet? What regimen?  How would this change for a patient with high risk cytogenetics?
6 Answers available
For patients with ER-negative HER2-ultralow breast cancer, how and when would you incorporate T-DXd?
Given that ER-negative patients were not enrolled to the DB06 trial, can results be extrapolated to this population?
2 Answers available
For patients with metastatic HER2-null breast cancer, do you offer trastuzumab deruxtecan based on the DAISY trial results?
4 Answers available
What clinical or logistical factors influence your choice of anti-CD38 antibody in first line treatment of Multiple Myeloma?
For example, per the IMROZ trial methodology, Isatuximab dosing does not change to monthly dosing until >18 cycles which can impact patient QoL and...
3 Answers available
Are you still recommending autologous stem cell transplantation (ASCT) for all eligible myeloma patients who achieve remission after induction with a quadruplet regimen?
Or can we omit it in older patients given efficacy of these regimens? Is transplant-eligibility still an important distinction up front given options ...
2 Answers available
Do you recommend utilizing daratumumab in the maintenance phase after a quadruplet induction for transplant eligible multiple myeloma?
4 Answers available
In patients with metastatic hormone receptor-positive, HER2-low breast cancer, how many and which lines of therapy would you recommend prior to using trastuzumab deruxtecan?
Are there any circumstances where use of T-DXd would supercede the use of CDK4/6 inhibitors or other non-chemotherapeutic options (PIK3CA etc?)
9 Answers available
How do you identify which patients are at highest risk for decompensation and most likely to benefit from NIV for pre-oxygenation prior to intubation?
2 Answers available
Does the experience level of the intubation operator affect outcomes related to pre-oxygenation with NIV versus an oxygen mask?
2 Answers available
Does the use of NIV for pre-oxygenation delay the time to intubation?
2 Answers available
What are the logistical challenges and time constraints of implementing NIV for pre-oxygenation in emergency settings compared to oxygen masks?
1 Answer available
Would bag-mask ventilation with a PEEP valve be a reasonable alternative to NIV for pre-oxygenation prior to intubation in settings where NIV is not easily accessible?
1 Answer available
Is there a subset of patients in whom pre-oxygenation with NRB or BVM could be safely pursued?
1 Answer available
When and how are you incorporating tumor sequencing to plan treatment of metastatic prostate cancer?
Given the FDA approvals for PARP inhibitors and combinations in mCRPC, when do you obtain NGS for mCRPC? Do you have a preferred assay?
5 Answers available
Are there scenarios where you would consider use of capivasertib for non-AKT pathway altered patients given the efficacy seen in the overall treatment population of the CAPItello-291 trial?
PFS curves appear similar between the AKT-altered vs overall study population in the trial publication. Is there any additional information available ...
3 Answers available
How does one approach maintenance treatment in transplant ineligible patients with newly diagnosed multiple myeloma?
Do the IMROZ and BENEFIT trials inform choice? In IMROZ, the high-risk population received only revlimid/dexamethasone maintenance. Should they have g...
2 Answers available
Are there strategies to mitigate the risk of developing ILD/pneumonitis while using trastuzumab deruxtecan?
Although grade 3 toxicity rates were low, ~10.5% experience some degree of ILD, are there strategies to reduce risk before treatment starts? Are ther...
3 Answers available
When, if ever, will you utilize T-DM1 in metastatic HER2+ breast cancer given trastuzumab deruxtecan's significantly improved efficacy vs T-DM1?
Given the results of DESTINY-Breast03, and T-DXd's labeled indication in second-line, what is now the role of TDM1 in the treatment armamentarium of H...
7 Answers available
Does tolerance of prior BTKi therapy or specific agent used (e.g., ibrutinib, acalabrutinib) influence your starting dose of pirtobrutinib?
2 Answers available
How does pirtobrutinib compare to other available therapies for relapsed/refractory CLL after BTK inhibitor treatment, particularly in terms of efficacy and tolerability?
2 Answers available
What post-protocol therapies did patients on the BRUIN trial in CLL receive, and how did these therapies impact outcomes?
3 Answers available
How do CLL patients with downstream treatment-resistant mutations such as PLCG2 respond to pirtobrutinib?
Are there other mutations/biomarkers in CLL which may specifically predict for response or resistance to pirtobrutinib?
4 Answers available
What clinical factors influence your first line treatment selection in advanced HCC?
Are there factors which would make you more likely to use atezo/bev vs durva/treme vs TKI?
4 Answers available
How do you choose between Atezolizumab/Bevacizumab (IMbrave 150) versus Durvalumab/Tremelimumab (HIMALAYA) in first-line metastatic hepatocellular cancer?
1 Answer available
Would you offer capivasertib+fulvestrant in a patient with metastatic HR+ HER2 negative breast cancer with PTEN mutation who has progressed on fulvestrant plus ribociclib?
3 Answers available
How do you define PIK3CA/AKT/PTEN alteration for capivasertib use?
Patient with stage IV ER+PR+Her2- breast cancer progressed after CDK4/6 inhibitor+AI and then on Elacestrant. Guardant 360 showed ESR1 mutation and PI...
2 Answers available
What disease characteristics will guide your choice of alpelisib plus fulvestrant (per SOLAR-1) versus capivasertib plus fulvestrant (per CAPItello-291) in PIK3CA mutated advanced ER+/HER2- breast cancer after progression on 1L ET regimen, given both are now approved in this population?
3 Answers available
Would you use sequential CDK 4/6 inhibitors in HR-positive metastatic breast CA in successive lines of therapy?
In MONALEESA-2, it appears ~22% of those in the ribcociclib group received a subsequent CDK4/6 inhibitor. What was the rationale and could this have i...
5 Answers available
Should we start performing universal germline mutation testing for all newly diagnosed breast cancer?
Given OlympiA trial with olaparib benefit for gBRCA+ patients?What are barriers that you foresee? In your practice who performs mutation testing and w...
5 Answers available
How will your approach to screening and diagnosis of early dementia change given newly available therapies for early Alzheimer's disease?
5 Answers available
What do you view as the future role for the combination of durvalumab + olaparib + chemotherapy in the management of patients with advanced/recurrent endometrial cancer following the DUO-E trial results?
Are there certain patient subgroups for whom you would use the IO+PARPi? Is there data from DUO-E regarding BRCA status and its potential impact on ...
2 Answers available
In light of the improved outcomes seen in patients receiving IO +/- olaparib, what role, if any, do you think pelvic radiation still plays in the management of patients with advanced endometrial cancer?
3 Answers available
Would you consider offering immunotherapy +/- olaparib to a patient with early-stage endometrial carcinoma for whom you are recommending adjuvant chemotherapy based on improved outcomes seen in RUBY/DUO-E/NRG-GY018?
If yes, would you apply this broadly or reserve the addition of IO to chemotherapy for patients with high-risk histologies (e.g., carcinosarcoma) or o...
2 Answers available
In a patient with HER2+ advanced endometrial cancer, do you include IO(+/- olaparib) in their treatment regimen, or only trastuzumab in addition to carboplatin/paclitaxel?
Does your decision depend on MMR status? Would you use the same approach for neoadjuvant treatment?In light of relevant trials including RUBY, GY018, ...
3 Answers available
Would you recommend adjuvant chemo+IO +/- olaparib for patients with occult stage III disease identified after staging surgery with no measurable residual disease?
DUO-E, GY-018, and RUBY included patients with stage III and IV endometrial cancer WITH measurable disease.Would your decision change based on the mis...
4 Answers available
For patients with advanced endometrial cancer, are the improved outcomes in PFS from DUO-E/RUBY/NRG-GY018 sufficient to move immunotherapy to the frontline for all presuming FDA approval?
Are there patients for whom you would still reserve IO for salvage/recurrent setting (eg IO + lenvatinib)? Would you base this on MMR status or other ...
2 Answers available
At what point do you consider a patient to have relapsing PMR?
How much cumulative prednisone exposure do you tolerate and how many attempts at tapering will you pursue before considering addition of a steroid spa...
4 Answers available
How clinically meaningful are the differences in the primary outcome between treatment and placebo groups in the CENTAUR trial?
Will these results change your practice?
5 Answers available
How will you approach tapering sarilumab in patients with PMR in remission?
After what interval of sustained remission will you attempt to taper, and will you do so by first widening the dosing interval?
2 Answers available
Would you avoid combining JAK inhibitors with IVIG given the risk of thromboembolism?
4 Answers available
How will you approach drug sequencing in patients with PMR given the SAPHYR data?
Will you initiate sarilumab as a first steroid sparing agent or will you still pursue a DMARD such as methotrexate before initiating sarilumab? To wha...
2 Answers available
How will you adjust your approach to steroid taper in patients with PMR also on sarilumab?
2 Answers available
What baseline and ongoing testing do you recommend for patients with PMR who are going to be on a prolonged steroid taper?
Do you universally perform baseline DEXA and Hgb A1C? How often are you obtaining routine labs?
2 Answers available
How do you explain the clinical benefit of lecanemab or donanemab to patients?
Do you feel the study outcomes are clinically meaningful?
3 Answers available
What patient factors prompt you to consider starting dupilumab in patients with COPD?
Does active smoking status influence this decision?
2 Answers available
Did the low rate of COPD exacerbations in the BOREAS cohort overall confound the results of the study?
2 Answers available
Are the results of the BOREAS trial generalizable to non-white populations?
The cohort in the study was predominantly white. Do these results highlight significant disparities in COPD care?
2 Answers available
Will you use FeNO testing in all COPD patients to determine whether they are candidates for therapy with dupilumab?
If so, would this be a consideration in all patients regardless of active smoking status? FeNO in active smokers has been questioned, could this have ...
2 Answers available
Is there a point at which further reduction in amyloid burden is no longer clinically meaningful or should the goal always be as much reduction as possible?
4 Answers available
How will you counsel patients regarding ARIA?
Do you see utility in trending serum neurofilament light chain levels or any alternative screening methods beyond MRI to help identify amyloid-related...
2 Answers available
How do you recommend tapering IVIG in patients whose inflammatory myositis has achieved remission?
4 Answers available
What makes a patient a good candidate for treatments targeting amyloid such as lecanemab or donanemab?
Are there patients in whom you would specifically avoid this class of treatments?
2 Answers available
Which myositis patients are good candidates for IVIG?
3 Answers available
How long can you treat dermatomyositis with IVIG?
3 Answers available
Are you routinely using neoadjuvant cemiplimab for cutaneous squamous cell carcinoma of any site?
Majority of patients on the seminal trial (Gross et al., PMID 36094839) had tumors isolated to head & neck, what was the rationale for this?
4 Answers available
Would you continue cemiplimab or pembrolizumab adjuvantly, following resection of initially unresectable cutaneous squamous cell carcinoma?
Do you base your decision on extent of residual disease?  Does the use of (neo)adjuvant immunotherapy have an impact on surgical site size or he...
4 Answers available
Do you consider downstaging neoadjuvant cemiplimab for borderline resectable CSCC in order to facilitate surgical resection?
3 Answers available
What role, if any, do biomarkers play in selecting appropriate patients for neoadjuvant cemiplimab in cutaneous squamous cell carcinoma?
3 Answers available
Would you consider adjuvant nivolumab to be the standard of care in stage II/III esophageal/GE junction cancer after completion of neoadjuvant chemoradiotherapy and surgery?
Based on CheckMate 577?Is DFS endpoint sufficient to establish SOC or is OS benefit needed?
4 Answers available
Would the concerns about respiratory side effects from sodium phenylbutyrate and taurusodiol change your management of patients with predominantly bulbar ALS?
3 Answers available
How do you monitor for pulmonary toxicity for patients on trastuzumab deruxtecan?
Would you obtain baseline PFT on all patients or only selected high risk patients? Would you repeat PFTs regularly or only if clinically symptomatic?&...
5 Answers available
When do you consider HER2-targeting antibody drug conjugates in the first line setting for metastatic HER2 positive, ER negative breast cancer?
Given strong TDXd efficacy in these patients is there a role to use it earlier than 2nd line? How does prior Her2-directed and/or taxane therapy...
5 Answers available
Would you consider PD-L1 score when deciding whether to incorporate durvalumab in first-line metastatic biliary cancer?
If so, what assay would you use in this population? Do we have data on TMB/PDL1 status of long-term survivors?
2 Answers available
How do you counsel patients on the side effects of sodium phenylbutyrate and taurursodiol?
3 Answers available
Do you typically assess plasma levels of the phosphorylated axonal neurofilament H subunit (pNF-H) in patients with ALS?
3 Answers available
Based on its mechanism of action, do you think sodium phenylbutyrate and taurursodiol could have benefit in other neurodegenerative disorders?
3 Answers available
Can durvalumab incorporation to gem+cis for advanced BTCs allow for earlier discontinuation of cytotoxic chemotherapy in patients exhibiting response?
TOPAZ-1 trial allowed for up to 8 cycles of gem/cis. Were there differences in chemotherapy duration/# cycles between treatment groups? Does use of du...
4 Answers available
What is your approach to patients with unresectable, node-negative perihilar cholangiocarcinoma who have undergone biliary stenting and have no evidence of distant disease?
If borderline resectable, can the TOPAZ regimen be considered for downstaging effects?
4 Answers available
How does data from the HIMALAYA trial impact your first line treatment selection for advanced HCC?
8 Answers available
If using durvalumab/tremelimumab for advanced HCC, must the tremelimumab be given with the first cycle of durvalumab?
Is there a difference in efficacy if dose is given later point during the course of therapy?
2 Answers available
Would you add durvalumab to gem+cis in a patient with recurrent cholangiocarcinoma after liver transplant?
How would you balance the OS benefit from TOPAZ-1 with the risks of immunotherapy in this or other high-risk populations?
2 Answers available
Do you offer durvalumab in combination with gemcitabine and cisplatin in patients with metastatic ampullary adenocarcinoma, given the fact that ABC-02 trial included patients with ampullary adenocarcinoma while TOPAZ trial excluded those patients?
2 Answers available
How do you select systemic therapy for advanced HCC patients with portal vein thrombosis?
2 Answers available
What is your treatment approach for a patient with metastatic hepatocellular carcinoma with Child's Pugh B cirrhosis?
How do you sequence systemic treatment options for in patients with Child's Pugh B (or greater) in context of IMbrave150 and HIMALAYA? When do you in...
4 Answers available
Based on the TOPAZ-1 study, do you now routinely include durvalumab in first line treatment of advanced bile duct cancer?
Is data sufficient to adopt this as the new standard of care? Can you comment on the reported regional and race-based variations in outcomes?  ...
3 Answers available
Do you offer patients with advanced endometrial cancer lower starting doses of lenvatinib when used in combination with pembrolizumab given high adverse event rates with 20 mg daily?
Is there a role for using pembrolizumab alone in microsatellite stable endometrial cancer if patients are unable to tolerate lenvatinib?
3 Answers available
What are real world exclusion criteria for the use of lenvatinib + pembrolizumab for advanced endometrial cancer?
Are there specific clinical or social scenarios that would preclude the use of this treatment?
2 Answers available
Is there a difference in survival or disease response between patients with recurrence free interval ≥1 vs <1 year from platinum-based cytotoxic therapy who are treated with pembrolizumab + lenvatinib?
In the KEYNOTE-775 study, what was the proportion of patients who had a recurrence free interval ≥1 year from platinum-based cytotoxic chemotherapy...
1 Answer available
Are there any data that suggest superiority of lenvatinib + pembrolizumab vs platinum-based cytotoxic chemotherapy for advanced or recurrent endometrial cancer?
Are there any planned trials to compare lenvatinib + pembrolizumab and platinum-based cytotoxic chemotherapy for advanced or recurrent endometrial can...
1 Answer available
Is there a difference in the incidence of serious immune-related adverse events with the lenvatinib + pembrolizumab combination vs pembrolizumab alone in endometrial cancer?
Anecdotally, I have seen more serious IRAEs in patients I'm treating with this regimen than anticipated. Is there higher risk with this drug combinati...
3 Answers available
When, if ever, would you consider lenvatinib + pembrolizumab as first line therapy for patients with stage IV microsatellite stable endometrial cancer?
Are there certain patient or disease related factors that would lead you to incorporate lenvatinib + pembrolizumab earlier?
1 Answer available
If there is HER2-low discordance between primary and subsequent breast cancer biopsies, in which scenarios would you choose to use trastuzumab deruxtecan?
For example, if the primary breast tumor was HER2 IHC 1+, but a metastatic site was HER2 IHC 0, would you still recommend using T-DXd? Will you chang...
4 Answers available
Are there concerns in use or dosing of immunotherapy agents in extreme obesity?
Do you have a BMI threshold where you would convert to weight-based dosing over flat dosing? Are certain agents of more or less concern - PD-1, PD-L1,...
3 Answers available
What is trastuzumab deruxtecan's activity for patients with CNS+ disease?
Is there evidence that T-DXd crosses the blood-brain barrier?
3 Answers available
When defining HER2-low status in breast cancer, are there certain IHC assays/techniques that are preferred?
Prior studies have shown that there can be significant variation between grading pathologists as to which samples are defined as HER2 IHC +1 versus HE...
4 Answers available
Will you offer olaparib + abiraterone for all patients with metastatic castrate resistant prostate cancer based on results of PROPEL trial?
Do you find the ibPFS endpoint sufficient to change practice for any or all patients, or will you await OS or other data/trials?
2 Answers available
How will you approach treatment sequencing and use of trastuzumab deruxtecan in hormone receptor-negative, HER2-low breast cancer?
Specifically, how do you consider T-DXd use in setting of other antibody-drug conjugates (e.g. sacituzumab vedotin)? Are there any special considerati...
4 Answers available
Given several PARP inhibitors approved or with emerging positive data in castrate resistant prostate cancer, how do you decide which one and when to use?
How do you differentiate between olaparib, rucaparib, niraparib, talazoparib?
2 Answers available
For a patient treated with abiraterone for first line metastatic prostate cancer, would you still use a combination of abiraterone/olaparib at a subsequent progression?
If yes, would you directly add olaparib at progression on abiraterone vs waiting to use abi/olaparib at a later line of therapy?
2 Answers available
Among non-HRRm castrate resistant prostate cancer patients, are there features predictive of response to PROPEL regimen of abiraterone/olaparib?
3 Answers available
What could explain the discordant results between PARP/abiraterone combinations in MAGNITUDE and PROpel in non-HRRm prostate cancer?
Is the benefit in PROpel driven by BRCA1/2 or ATM mutated tumors vs all comers?
1 Answer available
Does the overall conclusion of the CHANCE-2 trial make ticagrelor + ASA a worthwhile transition given the data showing cumulative hazard of stroke diverged during the first week and was subsequently similar, which suggests the benefit of ticagrelor over clopidogrel is seen predominantly soon after stroke?
4 Answers available
Are there differences in T-DXd efficacy along the spectrum of HER2 IHC expression to impact treatment decisions or sequencing?
For example, are you more likely to incorporate T-DXd earlier in sequence for 2+ vs 1+? Is there any justification to change our approach in HER2-zer...
3 Answers available
Is there a risk of CYP2C19 gene testing only being adopted by wealthier health systems, thereby creating a disparity gap in treatment?
What is the cost and accessibility of CYP2C19 gene testing? Does the limited availability of rapid genotyping techniques limit the clinical applicabil...
3 Answers available
Would you generalize the data from the CHANCE-2 trial to a broader clinic population given that the study was specific to Han Chinese patients?
How do you plan to incorporate the results of the CHANCE-2 trial (Wang et al., PMID 34708996) in your own practice?
3 Answers available
Do you recommend genetic testing after a patient on clopidogrel has a stroke based on the results of the CHANCE-2 trial?
3 Answers available
What is your process for assessing the "high risk" clinical features in gBRCA+ breast cancer in order to offer olaparib, given varying definitions of risk and recent changes in staging guidelines?
Definitions for "high risk" differ by whether patients receive neoadjuvant chemo and across other contemporary studies. Does the change in AJCC stagin...
3 Answers available
How do you approach CV risk assessment in RA patients when RA itself is associated with some degree of increased CV risk at baseline?
Recent articles regarding the use of JAK-Inhibition in RA have suggested to avoid in patients with increased CV risk.  However, RA itself is cons...
2 Answers available
Would you recommend that a patient with stable coronary artery disease and well-controlled RA on a JAK inhibitor continue on their current therapy?
2 Answers available
Do you still plan to offer tofacitinib to RA patients over 65 if they have one or more additional CV risk factors?
2 Answers available
How do you counsel patients regarding the cardiovascular and cancer risks associated with tofacitinib?
2 Answers available
Would you recommend adjuvant olaparib in a premenopausal BRCA1+ woman with stage IA pT1bN0 ER/PR+ HER2- breast cancer and a high OncoType score?
The OncotypeDx score was 51 in this scenario. 
3 Answers available
What could explain the contradictory results between CheckMate 274, IMvigor010, and AMBASSADOR?
3 Answers available
How would you approach treatment of a patient with metastatic NSCLC with PD-L1>1% and HER2-mutation?
Does this change for PDL1 1-49% vs >50%? Will you be more likely to employ other checkpoint inhibitors before use of HER2 targeting therapy? Or sta...
3 Answers available
Do you plan to offer adjuvant olaparib to all gBRCA+ breast cancer whether TNBC or HR+?
In subset analyses of OlympiA there seems to be smaller magnitude of benefit among HR+ patients. In your opinion, should adjuvant olabarib be offered ...
3 Answers available
Can adjuvant nivolumab for bladder CA as per Checkmate 274 be extrapolated for the concurrent chemoRT bladder preservation setting?
4 Answers available
In patients who receive neoadjuvant pembrolizumab and chemotherapy for TNBC, how will you manage adjuvant treatment if they have a germline BRCA mutation?
Would you continue pembrolizumab? Would you introduce olaparib? If using both, how would you sequence? 
5 Answers available
When is the ideal time to start adjuvant nivolumab after radical surgery in urothelial carcinoma?
Is a 3 month delay too long in someone who had postoperative complications?
2 Answers available
Would you offer first line atezolizumab plus bevacizumab in unresectable/metastatic hepatocellular carcinoma based on the IMbrave 150 data?
6 Answers available
How do you sequence capecitabine and olaparib, if at all, in patients with BRCA+ TNBC and residual disease after neoadjuvant chemotherapy?
5 Answers available
Can the results of Checkmate 577 be applied to patients who do not undergo surgery following chemoradiation because of a clinical complete response?
What about for a patient with complete radiographic response who declines surgical management?
3 Answers available
How do you interpret efficacy of trastuzumab deruxtecan based on HER2 mutation type and/or level of HER2 overexpression?
How and when do you plan to perform HER2 testing in patients with NSCLC?
2 Answers available
How do you address and mitigate neutropenia in patients with TNBC receiving sacituzumab govitecan in 3rd line or beyond?
Many of the patients on ASCENT trial were heavily pre-treated and require growth factors. With the day 1,8 treatment cycle, is there a way to minimize...
4 Answers available
Do you find data from phase 2 DESTINY-LUNG01 study sufficient to change practice in HER2 mutant NSCLC or is a phase 3 study still needed?
How does trastuzumab deruxtecan compare to other HER2 targeted strategies?
3 Answers available
How does use of adjuvant nivolumab impact your subsequent use of immunotherapy + chemo in a PDL1+ GEJ cancer with metastatic relapse?
What factors would influence your approach?
3 Answers available
Should we be giving adjuvant nivolumab to all eligible esophageal/GEJ cancer, irrespective of the PD-L1 status of the tumor?
Are there other treatment variations by clinical subsets (eg tumor location, histology, stage II vs III, other biomarkers) seen in CM577 or other data...
3 Answers available
Can CM577 regimen of adjuvant nivolumab s/p neoadjuvant chemoRT with residual disease following surgery be extrapolated to patients with R1 resection unable to undergo re-resection?
CheckMate 577 only included patients with R0 resection.For R1 resections, guidelines suggest observation vs re-resection only.  
3 Answers available
What is your approach to a patient with metastatic lung cancer with HER2 mutant NSCLC who is not a trial candidate?
How are you thinking about sequencing therapies for these patients (IO vs chemo vs T-Dxd)? Are the data from DESTINY-Lung01 strong enough to warrant e...
3 Answers available
What strategies can be employed to manage interstitial lung disease seen with trastuzumab deruxtecan?
Can patients be re-challenged after developing ILD? Is the toxicity seen with T-Dxd a potential barrier to use?  Do you feel the dosing used in...
2 Answers available
In which scenarios would you utilize sacituzumab govitecan earlier than third line in the treatment of metastatic TNBC?
Given seemingly improved efficacy in ASCENT patients who had less prior treatment, would you consider use after only one prior agent rather than two? ...
4 Answers available
How has the ASCENT trial impacted your management of previously treated metastatic TNBC?
Are there specific patient cohorts in whom you will more preferentially use sacituzumab govitecan? Can data from ASCENT be applied to patients with C...
3 Answers available
Are there known biomarkers predictive of response or resistance to sacituzumab govitecan which should be incorporated into treatment decisions for metastatic TNBC?
Are there differences in outcome among the BRCA mutated subgroup, or others?
2 Answers available
How do you counsel patients with metastatic TNBC on their various treatment options after progression on first line regimens?
To what degree do you factor in patient preference when choosing among available treatments? Are there features of each regimen that you emphasize in ...
3 Answers available
Should the use of avacopan be limited to those patients at increased risk of steroid toxicity given the anticipated high cost of this medication?
ADVOCATE trial
1 Answer available
How should the results of the ADVOCATE trial be applied in AAV patients who receive rituximab induction and maintenance therapy?
In the ADVOCATE trial, patients were not re-dosed with rituximab.
1 Answer available
Are there particular subsets of AAV patients in which avacopan is more effective?
E.g., MPO vs PR3, newly diagnosed vs relapsed, renal involvement. Acknowledge that the ADVOCATE study was not powered to detect these differences, but...
1 Answer available
Should we consider radiation therapy for patients with N2 EGFRm NSCLC who will receive osimertinib, though RT was excluded on ADAURA?
Conversely: In a patient with N2 EGFR+ NSCLC receiving radiation, would you still consider use of osimertinib?
4 Answers available
Does stage of resected EGFRm NSCLC impact your treatment decisions for use of adjuvant osimertinib?
What was the magnitude of benefit for patients with EGFRm NSCLC by stage?  Are you still considering adjuvant osimertinib for patients with earl...
5 Answers available
Are you ordering EGFR testing on all patients with NSCLC after complete resection in light of ADAURA?
If patients do recur, do you perform these tests on the initial surgical specimen or on tissue from a fresh biopsy (or both?)
6 Answers available
How does the lack of mandated PET or brain MRI in the ADAURA trial impact your interpretation of the results?
Is data available regarding the percentages of patients in each arm who underwent staging PET or the breakdown of CNS imaging modalities?
4 Answers available
Should 3 years of adjuvant osimertinib be the standard of care for resected Stage IB-IIIA EGFRm NSCLC?
6 Answers available
How late after surgery would you consider prescribing osimertinib as adjuvant therapy in patients with resected EGFRm NSCLC?
3 Answers available
How will the ADAURA study impact your use of adjuvant chemotherapy?
Are the rates of adjuvant chemotherapy used in ADAURA consistent with real-world practice?
4 Answers available
Is anticoagulation a relative contraindication to atezolizumab/bevacizumab for advanced HCC?
For example in a patient with a history of PE?
3 Answers available
For patients with HCC receiving atezo/bev, would you advise any other clinical investigations scheduled during treatment other than basic lab monitoring?
i.e. EGD surveillance for varices?
3 Answers available
When would you continue atezolizumab/bevacizumab beyond progression in advanced HCC?
What parameters do you use to decide to treat beyond progression? Is there any efficacy data from this specific study subgroup in IMbrave150?
2 Answers available
Are there any biomarkers that might indicate who might be responders to atezolizumab/bevacizumab for HCC?
ex. VEGFR2 expression, inflammatory signature, PDL1, etc.
2 Answers available
How do you manage patients on atezolizumab/bevacizumab with advanced HCC who develop arterial thrombosis?
Do you continue atezolizumab alone? Would you avoid anticoagulation?
6 Answers available
For patients with HCC that have stable disease on immunotherapy alone, would you consider adding bevacizumab at the time of disease progression and continue immunotherapy?
2 Answers available
How do you decide between systemic vs. arterially directed therapies in the first line setting for unresectable HCC?
In light of the SIRveNIB trial results and now IMbrave150, what is the role of intra-arterial therapy now?
2 Answers available
Would you use upfront atezo/bev in a patient with HCC and untreated hepatitis?
3 Answers available
Do you refer all of your patients for EGD prior to initiation of atezolizumab/bevacizumab for advanced HCC?
Do you screen even asymptomatic patients?
4 Answers available


Papers discussed in this category

JCO Precision Oncology, 2017 May 31
Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making
The New England journal of medicine, 2016-08-04
Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer.
NEJM Evidence, 2022 Jun 3
Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer
The New England journal of medicine, 2012-01-12
Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.
The New England journal of medicine, 2012-11-08
Trastuzumab emtansine for HER2-positive advanced breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-10-10
T-DM1 Activity in Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancers That Received Prior Therapy With Trastuzumab and Pertuzumab.
N Engl J Med,
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.
N Engl J Med, 2019 Dec 11
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer.
N Engl J Med,
Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-09-01
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy.
Clinical cancer research : an official journal of the American Association for Cancer Research, 2017 May 22
MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR/HER2 Metastatic Breast Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023 May 19
Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: MAINTAIN Trial.
J Hepatol, 2021 Nov 19
BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update.
N Engl J Med, 2020 May 14
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.
J Hepatol, 2021 Dec 11
Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma.
Clin. Cancer Res., 2015 Oct 23
Safety and Pharmacokinetics of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma.
Invest New Drugs, 2015 Apr 12
Sorafenib treatment in Child-Pugh A and B patients with advanced hepatocellular carcinoma: safety, efficacy and prognostic factors.
J Hepatol, 2021 May 26
CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis.
NEJM Evidence, 2022 June 6
Tremelimumab Plus Durvalumab in Unresectable Hepatocellular Carcinoma
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009-04-10
Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301.
Cancer, 2019-09-15
Nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh class B cirrhosis: Safety and clinical outcomes in a retrospective case series.
N Engl J Med, 2021 Sep 18
Trastuzumab Deruxtecan in -Mutant Non-Small-Cell Lung Cancer.
The New England journal of medicine, 2018-05-31
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015-12-01
Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial.
N Engl J Med, 2020 Sep 19
Osimertinib in Resected -Mutated Non-Small-Cell Lung Cancer.
J Clin Oncol, 2020 Dec 04
Lessons From ADAURA on Adjuvant Cancer Drug Trials: Evidence, Ethics, and Economics.
N Engl J Med, 2022 Oct 06
Trial of Intravenous Immune Globulin in Dermatomyositis.
Cancer Treat Rev, 2022 Mar 12
Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)-related interstitial lung disease/pneumonitis-Focus on proactive monitoring, diagnosis, and management.
Liver Cancer, 2019 Sep 18
A New Treatment Option for Intermediate-Stage Hepatocellular Carcinoma with High Tumor Burden: Initial Lenvatinib Therapy with Subsequent Selective TACE.
British journal of cancer, 2011-06-07
Recurrence and survival after pathologic complete response to preoperative therapy followed by surgery for gastric or gastrooesophageal adenocarcinoma.
N Engl J Med, 2021-04-01
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer.
N Engl J Med, 2022 Sep 12
Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma.
Front Oncol, 2023 Jan 04
Case report: The power of immunotherapy in advanced cutaneous squamous cell carcinoma.
Br J Dermatol, 2015 Aug 08
Efficacy of neoadjuvant cetuximab alone or with platinum salt for the treatment of unresectable advanced nonmetastatic cutaneous squamous cell carcinomas.
Lancet, 1998 Jul 25
Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. PORT Meta-analysis Trialists Group.
Int. J. Radiat. Oncol. Biol. Phys., 2008-11-01
Impact of postoperative radiation therapy on survival in patients with complete resection and stage I, II, or IIIA non-small-cell lung cancer treated with adjuvant chemotherapy: the adjuvant Navelbine International Trialist Association (ANITA) Randomized Trial.
N. Engl. J. Med., 2019 Dec 11
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.
J Clin Oncol, 2020 May 29
Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial.
Nature medicine, 2024 Jun 02
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial.
J Clin Oncol, 2011 Jun 1
International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial.
Lancet Oncol., 2014 Dec 11
Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial.
N Engl J Med,
Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma.
Lancet Oncol, 2021 Mar 12
Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2024 Oct 11
Adjuvant Nivolumab in High-Risk Muscle-Invasive Urothelial Carcinoma: Expanded Efficacy From CheckMate 274.
The New England journal of medicine, 2024 Sep 15
Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer.
N Engl J Med, 2021 Feb 18
Avacopan for the Treatment of ANCA-Associated Vasculitis.
Lancet (London, England), 2017-02-04
Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.
British journal of haematology, 2018-07
A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma.
The New England journal of medicine, 2019-05-30
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.
J Geriatr Oncol, 2021 Mar 06
Bortezomib in first-line therapy is associated with falls in older adults with multiple myeloma.
Leukemia, 2018 Apr 25
Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023 Sep 27
Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple Myeloma.
N Engl J Med, 2021 Jun 03
Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer
Ann Surg Oncol, 2019 Jul 24
Consensus Guidelines on Genetic` Testing for Hereditary Breast Cancer from the American Society of Breast Surgeons.
J Clin Oncol, 2020 Mar 03
Evaluation of Germline Genetic Testing Criteria in a Hospital-Based Series of Women With Breast Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-02-20
Underdiagnosis of Hereditary Breast Cancer: Are Genetic Testing Guidelines a Tool or an Obstacle?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-08-20
Should All Patients With a Diagnosis of Breast Cancer Undergo Expanded Panel Testing?
Cancer, 2021 Mar 15
Germline genetic testing in breast cancer: Rationale for the testing of all women diagnosed by the age of 60 years and for risk-based testing of those older than 60 years.
J Clin Oncol, 2015 Nov 1
American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2024 Jan 04
Germline Testing in Patients With Breast Cancer: ASCO-Society of Surgical Oncology Guideline.
N. Engl. J. Med.,
Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy.
N. Engl. J. Med., 2017 Jun 04
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.
Annals of oncology : official journal of the European Society for Medical Oncology, 2019-04-01
OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer.
BMC Cancer, 2018 Mar 07
Prevalence of pathogenic BRCA1/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer history.
N Engl J Med,
Olaparib for Metastatic Germline BRCA-Mutated Breast Cancer.
JCO Oncol Pract, 2022 Jan 07
Q and A: A New Standard of Care for Germline and/or Mutation Carriers With Early-Stage Breast Cancer.
The New England journal of medicine, 2018-08-23
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.
N. Engl. J. Med.,
Pembrolizumab for Early Triple-Negative Breast Cancer.
Lancet Oncol, 2020 Aug 06
Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study.
The Lancet. Oncology, 2018-04
Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.
JAMA Oncol,
Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial.
European urology, 2014-07
Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001-02-01
Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients.
Lancet, 2020 Mar 05
Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial.
Nature, 2021 Jun 16
ctDNA guiding adjuvant immunotherapy in urothelial carcinoma.
European urology, 2005 Apr 25
Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration.
N Engl J Med, 2021 Apr 22
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.
Cancer Discov, 2021 Aug 17
Parallel Genomic Alterations of Antigen and Payload Targets Mediate Polyclonal Acquired Clinical Resistance to Sacituzumab Govitecan in Triple-Negative Breast Cancer.
Ann Oncol, 2021 Mar 16
Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial.
Annals of oncology : official journal of the European Society for Medical Oncology, 2001-09
Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer.
Cochrane Database Syst Rev, 2021 May 26
Capecitabine for hormone receptor-positive versus hormone receptor-negative breast cancer.
The Lancet. Oncology, 2017-06
Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-10-10
Safety and Efficacy of T-DM1 Plus Neratinib in Patients With Metastatic HER2-Positive Breast Cancer: NSABP Foundation Trial FB-10.
JAMA Oncol,
Tucatinib Combined With Ado-Trastuzumab Emtansine in Advanced ERBB2/HER2-Positive Metastatic Breast Cancer: A Phase 1b Clinical Trial.
Annals of surgery, 2009-05
Post-treatment endoscopic biopsy is a poor-predictor of pathologic response in patients undergoing chemoradiation therapy for esophageal cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011-05-20
Validation of a novel staging system for disease-specific survival in patients with breast cancer treated with neoadjuvant chemotherapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008-01-10
Combined use of clinical and pathologic staging variables to define outcomes for breast cancer patients treated with neoadjuvant therapy.
The New England journal of medicine, 2018-07-12
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer.
Annals of oncology : official journal of the European Society for Medical Oncology, 2019-08-01
Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry.
J Thorac Oncol, 2020 Jan 13
Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients With Advanced NSCLC With BRAF, HER2, or MET Mutations or RET Translocation: GFPC 01-2018.
J Immunother Cancer, 2019 Jan 21
A novel anti-HER2 anthracycline-based antibody-drug conjugate induces adaptive anti-tumor immunity and potentiates PD-1 blockade in breast cancer.
ESMO Open, 2021 Aug 31
Targeting HER2 in non-small-cell lung cancer (NSCLC): a glimpse of hope? An updated review on therapeutic strategies in NSCLC harbouring HER2 alterations.
J Clin Oncol, 2021 Aug 03
Adjuvant PARP Inhibitors in Patients With High-Risk Early-Stage HER2-Negative Breast Cancer and Germline Mutations: ASCO Hereditary Breast Cancer Guideline Rapid Recommendation Update.
The New England journal of medicine, 2024 Sep 15
Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma.
N. Engl. J. Med.,
Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.
JAMA oncology, 2019-06-01
Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial.
Transpl Int, 2010 May 20
Liver transplantation for cholangiocarcinoma.
NEJM Evidence, 2022 Jun 1
Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer
Eur J Surg Oncol,
Prevention of implantation metastases after resection of proximal bile duct tumours with pre-operative low dose radiation therapy.
World J Surg, 2019 Apr
Our Rationale of Initiating Neoadjuvant Chemotherapy for Hilar Cholangiocarcinoma: A Proposal of Criteria for "Borderline Resectable" in the Field of Surgery for Hilar Cholangiocarcinoma.
J Surg Oncol, 2020 Sep 24
Outcomes of neoadjuvant therapy for cholangiocarcinoma: A review of existing evidence assessing treatment response and R0 resection rate.
World J Gastrointest Surg, 2019 Jun 27
Neoadjuvant therapy in the treatment of hilar cholangiocarcinoma: Review of the literature.
Annals of oncology : official journal of the European Society for Medical Oncology, 2024 Feb 19
Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma.
Ann Rheum Dis, 2016 Oct 03
EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update.
N Engl J Med,
Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis.
The Lancet. Oncology, 2019-06
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study.
J Clin Oncol, 2020 Feb 14
Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study.
JCO oncology practice, 2023 May 19
Detecting and Managing T-DXd-Related Interstitial Lung Disease: The Five "S" Rules.
JAMA Netw Open, 2022 Feb 01
Outcomes Among Patients With or Without Obesity and With Cancer Following Treatment With Immune Checkpoint Blockade.
J Clin Oncol, 2021 May 03
Appropriate Systemic Therapy Dosing for Obese Adult Patients With Cancer: ASCO Guideline Update.
The Lancet. Oncology, 2018-03
Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis.
Nature medicine, 2019-01
Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade.
J Immunother Cancer,
Obesity diminishes response to PD-1-based immunotherapies in renal cancer.
N Engl J Med, 2021 Oct 28
Ticagrelor versus Clopidogrel in Loss-of-Function Carriers with Stroke or TIA.
The New England journal of medicine, 2018-07-19
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
N Engl J Med, 2013 Jun 26
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
N Engl J Med,
Ticagrelor and Aspirin or Aspirin Alone in Acute Ischemic Stroke or TIA.
N Engl J Med, 2022 Jun 05
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.
N Engl J Med,
Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer.
Oncologist,
Immune Checkpoint Inhibitors in the Treatment of Breast Cancer Brain Metastases.
J. Clin. Oncol., 2018 May 30
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update.
Virchows Arch, 2022 Aug 16
Comparison of HercepTest™ mAb pharmDx (Dako Omnis, GE001) with Ventana PATHWAY anti-HER-2/neu (4B5) in breast cancer: correlation with HER2 amplification and HER2 low status.
Int J Mol Sci, 2020 Sep 03
Progression-Free Survival and Overall Survival of CDK 4/6 Inhibitors Plus Endocrine Therapy in Metastatic Breast Cancer: A Systematic Review and Meta-Analysis.
The New England journal of medicine, 2024 Sep 15
Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer.
Eur Urol, 2020 Jun 09
Five-year Survival Prediction and Safety Outcomes with Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer from the PREVAIL Trial.
Cancers (Basel), 2022 Mar 28
Efficacy and Safety of Atezolizumab and Bevacizumab in the Real-World Treatment of Advanced Hepatocellular Carcinoma: Experience from Four Tertiary Centers.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-08-01
Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study.
The Lancet. Oncology, 2015-11
Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial.
N Engl J Med, 2021 Feb 13
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.
J Clin Oncol, 2020 Mar 13
Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer.
N Engl J Med, 2022 Jan 19
Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer.
N Engl J Med, 2015 Apr 19
Pembrolizumab versus Ipilimumab in Advanced Melanoma.
Gynecol Oncol, 2021 May 03
Toxicity and efficacy of the combination of pembrolizumab with recommended or reduced starting doses of lenvatinib for treatment of recurrent endometrial cancer.
Int J Mol Sci, 2022 May 24
The Common Cellular Events in the Neurodegenerative Diseases and the Associated Role of Endoplasmic Reticulum Stress.
N Engl J Med, 2020 Sep 3
Trial of Sodium Phenylbutyrate-Taurursodiol for Amyotrophic Lateral Sclerosis.
Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases, 2010
Clinical significance in the change of decline in ALSFRS-R.
J Pathol Transl Med, 2019 Nov 06
HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation.
Endocrine reviews, 2008-04
Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance.
Clinical cancer research : an official journal of the American Association for Cancer Research, 2015-09-01
Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 Therapy.
Clinical chemistry, 2020 Nov 01
Quantification of Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor 2 Protein Expression in Bone Biopsies by Targeted Mass Spectrometry without Acid Decalcification.
The oncologist, 2013 May 30
Discordances in estrogen receptor status, progesterone receptor status, and HER2 status between primary breast cancer and metastasis.
Nature medicine, 2023 Jul 24
Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial.
J. Clin. Oncol., 2018 Mar 14
Postoperative Concurrent Chemoradiotherapy Versus Postoperative Radiotherapy in High-Risk Cutaneous Squamous Cell Carcinoma of the Head and Neck: The Randomized Phase III TROG 05.01 Trial.
N Engl J Med, 2023 Mar 27
Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer.
N Engl J Med, 2023 Mar 27
Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer.
Journal of clinical oncology : Official Journal of the American Society of Clinical Oncology, 2023 Oct 21
Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-07-10
Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu.
Lancet (London, England), 2023 Oct 20
Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023 Oct 23
Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial.
NEJM evidence, 2022 Jun 06
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma.
JAMA, 2023 Jul 17
Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial.
Alzheimer's & dementia : the journal of the Alzheimer's Association, 2022 Aug 15
The AHEAD 3-45 Study: Design of a prevention trial for Alzheimer's disease.
The journal of prevention of Alzheimer's disease, 2022
Blood Biomarkers from Research Use to Clinical Practice: What Must Be Done? A Report from the EU/US CTAD Task Force.
Annals of internal medicine, 2004-10-05
Prednisone plus methotrexate for polymyalgia rheumatica: a randomized, double-blind, placebo-controlled trial.
The New England journal of medicine, 2023 Oct 05
Sarilumab for Relapse of Polymyalgia Rheumatica during Glucocorticoid Taper.
Annals of the rheumatic diseases, 1996 Apr
Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis?
The Journal of rheumatology, 1996 Sep
The use of methotrexate in polymyalgia rheumatica.
International journal of clinical pharmacology and therapeutics, 2021 May
Methotrexate for treating polymyalgia rheumatica: A meta-analysis of randomized controlled trials.
Annals of the rheumatic diseases, 2022 Feb 24
Tocilizumab in patients with new onset polymyalgia rheumatica (PMR-SPARE): a phase 2/3 randomised controlled trial.
JAMA, 2022 Sep 20
Effect of Tocilizumab on Disease Activity in Patients With Active Polymyalgia Rheumatica Receiving Glucocorticoid Therapy: A Randomized Clinical Trial.
Ann Rheum Dis, 2015 Oct
2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative.
Arthritis care & research, 2023 Aug 10
Treatment of Polymyalgia Rheumatica by Rheumatology Providers: Analysis from the American College of Rheumatology RISE Registry.
Open access rheumatology : research and reviews, 2016
Polymyalgia rheumatica: observations of disease evolution without corticosteroid treatment.
Arthritis care & research, 2023 Oct 26
2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis.
Rheumatology advances in practice, 2021 Nov 27
Fragility fractures and prescriptions of medications for osteoporosis in patients with polymyalgia rheumatica: results from the PMR Cohort Study.
N. Engl. J. Med.,
Alpelisib for -Mutated, Hormone Receptor-Positive Advanced Breast Cancer.
The New England journal of medicine, 2023 Jun 01
Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer.
The Lancet. Haematology, 2023 Sep 11
Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial.
The Lancet. Oncology, 2021 Sep 13
Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial.
Lancet, 2019 Jun 03
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study.
Blood,
Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial.
The New England journal of medicine, 2023 Dec 12
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013-09-10
Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.
J Clin Oncol, 2022 May 18
Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial.
The oncologist, 2022 Mar 28
Alpelisib Plus Fulvestrant or Letrozole Demonstrates Sustained Benefits Across Subgroups of Patients with PIK3CA-Mutated HR+/HER2- Advanced Breast Cancer.
The Journal of clinical investigation, 2010-07
Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer.
Science translational medicine, 2015-04-15
PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer.
Cancer discovery, 2020 May 13
The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor-Positive Metastatic Breast Cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research, 2022 Mar 01
Functional Mapping of AKT Signaling and Biomarkers of Response from the FAIRLANE Trial of Neoadjuvant Ipatasertib plus Paclitaxel for Triple-Negative Breast Cancer.
Molecular cancer therapeutics, 2012 Jan 31
Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background.
Signal transduction and targeted therapy, 2021 Dec 16
Targeting PI3K/Akt signal transduction for cancer therapy.
International journal of molecular sciences, 2021 Dec 16
Targeting AKT in ER-Positive HER2-Negative Metastatic Breast Cancer: From Molecular Promises to Real Life Pitfalls?
The New England journal of medicine, 2022 Feb 24
Mechanisms of Resistance to Noncovalent Bruton's Tyrosine Kinase Inhibitors.
N Engl J Med, 2023 Jul 6
Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia.
Blood advances, 2023 Jun 27
BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib.
Blood advances, 2022 Oct 25
Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistance.
The Lancet. Oncology, 2018-01
Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial.
The New England journal of medicine, 2018-03-22
Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.
Blood advances, 2024 Mar 26
Venetoclax-rituximab is active in patients with BTKi-exposed CLL, but durable treatment-free remissions are uncommon.
Haematologica, 2024 Jun 01
Pirtobrutinib venetoclax in covalent Bruton tyrosine kinase inhibitor-pretreated chronic lymphocytic leukemia: a matching-adjusted indirect comparison.
Lancet Oncol, 2021 Nov 11
Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial.
The Lancet. Oncology, 2021 Oct 13
Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial.
The New England journal of medicine, 2024 Jun 03
Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Nature medicine, 2024 Jun 03
Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial.
The New England journal of medicine, 2024 Jun 13
Noninvasive Ventilation for Preoxygenation during Emergency Intubation.
Critical care medicine, 2019 Apr
Compared Efficacy of Four Preoxygenation Methods for Intubation in the ICU: Retrospective Analysis of McGrath Mac Videolaryngoscope Versus Macintosh Laryngoscope (MACMAN) Trial Data.
European journal of anaesthesiology, 2015 Dec
Preoxygenation by spontaneous breathing or noninvasive positive pressure ventilation with and without positive end-expiratory pressure: A randomised controlled trial.
The American journal of emergency medicine, 2016 May 28
The utility of noninvasive nasal positive pressure ventilators for optimizing oxygenation during rapid sequence intubation.
The New England journal of medicine, 2017-04-06
Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma.
N Engl J Med, 2022 Jun 05
Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma.
The New England journal of medicine, 2023 Oct 20
Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999-02
Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006 Dec 01
Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer.
The Lancet. Respiratory medicine, 2022 Oct 14
Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial.
J Clin Oncol, 2023 Mar 10
Multicenter Phase II Clinical Trial of Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy for Patients With High-Grade Upper Tract Urothelial Carcinoma.
The New England journal of medicine, 2024 Mar 07
Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.

Related Topics

Copyright © 2025 theMednet
All Rights Reserved.